A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare. The Phase 1 clinical trial will help determine if EP-100 is safe and effective for use among patients with solid cancer tumors, with fewer side effects than chemotherapy or radiation treatment. According to Ramesh K. Ramanathan, MD, principal investigator for the trial in Scottsdale, the drug is a membrane-disrupting peptide (tMDP) designed to "seek and destroy" cancer cells by targeting those with excessive luteinizing hormone releasing hormone (LHRH) receptors. Excessive LHRH receptors are found in a wide range of cancers, including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers. EP-100 will be administered intravenously for three out of four weeks. Once the maximum tolerated dose has been established, additional subjects with specific diagnoses of either breast, ovarian, endometrial, pancreatic or prostate cancer will be enrolled. EP-100 is produced by Esperance Pharmaceuticals of Baton Rouge, La., and was culled from a range of drugs tested at TGen Drug Development Services (TD2) in Scottsdale.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment